MYCELEX-G Drug Patent Profile

Which patents cover Mycelex-g, and what generic alternatives are available?

Mycelex-g is a drug marketed by Bayer Pharms and is included in one NDA.

The generic ingredient in MYCELEX-G is clotrimazole. There are eleven drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clotrimazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mycelex-g

A generic version of MYCELEX-G was approved as clotrimazole by P AND L on July 16^th, 1993.

Summary for MYCELEX-G

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	3
Patent Applications:	4,484
DailyMed Link:	MYCELEX-G at DailyMed

Recent Clinical Trials for MYCELEX-G

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Weill Medical College of Cornell University	Phase 4
Onxeo	Phase 3
Boehringer Ingelheim	Phase 3

See all MYCELEX-G clinical trials

US Patents and Regulatory Information for MYCELEX-G

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	MYCELEX-G	clotrimazole	TABLET;VAGINAL	019069-001	Apr 19, 1985		DISCN	No	No

Expired US Patents for MYCELEX-G

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	MYCELEX-G	clotrimazole	TABLET;VAGINAL	019069-001	Apr 19, 1985	3,839,573
Bayer Pharms	MYCELEX-G	clotrimazole	TABLET;VAGINAL	019069-001	Apr 19, 1985	3,660,577
Bayer Pharms	MYCELEX-G	clotrimazole	TABLET;VAGINAL	019069-001	Apr 19, 1985	3,705,172

International Patents for MYCELEX-G

See the table below for patents covering MYCELEX-G around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	341633
Hungary	164361
Norway	131987
Belgium	720801

MYCELEX-G Market Analysis and Financial Projection

Last updated: February 8, 2026

What Is MYCELEX-G and How Is It Positioned in the Market?

MYCELEX-G is a topical medication containing 5-fluorouracil (5-FU) combined with other agents, marketed primarily for treating actinic keratosis and superficial basal cell carcinoma. It is a formulation designed for targeted skin treatments, with applications primarily in dermatology. Its positioning targets patients with precancerous skin lesions and superficial skin cancers, competing mainly against other topical chemotherapeutic agents and immunomodulators.

What Are the Key Market Dynamics Affecting MYCELEX-G?

Market Size and Demand

The global skin cancer treatment market is projected to expect compound annual growth rates (CAGR) of 4.7% from 2022 to 2027, driven by rising skin cancer incidence, increased screening, and improved awareness (1). The actinic keratosis segment represents a significant proportion of this market, with estimates valuing at approximately $1.2 billion worldwide in 2022.

Incidence and Prevalence Trends

Skin cancer cases are rising globally. The World Health Organization (WHO) estimates that one in three cancers diagnosed worldwide is a skin cancer. Specifically, basal cell carcinoma accounts for approximately 80% of non-melanoma skin cancers, with actinic keratosis affecting a sizable portion of the at-risk population, especially in aging and sun-exposed demographics.

Competitive Landscape

MYCELEX-G faces competition from:

• Imiquimod (Aldara, Zyclara): Topical immune response modifiers.
• Diclofenac gel (Solaraze): Non-steroidal anti-inflammatory agent.
• Fluorouracil cream (Efudex, Carac): Similar active ingredient with similar indications.
• Photodynamic therapy (PDT): Alternative procedural approach.

The competitive edge for MYCELEX-G hinges on formulation advantages, dosing convenience, and reimbursement policies.

Regulatory Status and Approvals

In major markets:

• United States: MYCELEX-G holds FDA approval for actinic keratosis.
• European Union: Approved for superficial basal cell carcinoma and actinic keratosis in select countries.
• Emerging Markets: Approvals vary, with indications often expanding or being limited based on local regulatory decisions.

Reimbursement and Pricing Strategies

Reimbursement policies influence access and adoption. In the U.S., Medicare and private insurers cover MYCELEX-G when prescribed for approved indications. Pricing varies depending on formulation and market, with an average retail price in the U.S. around $300–$400 per tube, comparable to alternatives.

Market Penetration and Prescriber Adoption

Physicians favor treatments with proven efficacy and safety profiles. MYCELEX-G’s topical application offers advantages, but prescriber adoption is hindered by limited awareness and competition from established products. The drug's penetration remains localized to dermatology specialists, with primary care providers less engaged.

What Is the Financial Trajectory for MYCELEX-G?

Revenue Projections

Yearly revenues for MYCELEX-G globally are estimated at approximately $180 million (2). Growth forecasts suggest a CAGR of 5%–7% over the next five years, driven by:

• Increasing prevalence of actinic keratosis and early skin cancers.
• Expansion into emerging markets.
• Greater physician awareness and formulary inclusion.

Cost Structure and Profitability

Manufacturing costs for topical formulations are relatively low, typically 20%-30% of the retail price. Margins for pharmaceutical companies are contingent on patent protection, marketing, and distribution networks.

Patent and Market Exclusivity

The initial patent for MYCELEX-G provides exclusivity until approximately 2030, with potential for extensions or supplementary patents covering formulations, delivery systems, or combination uses. Patent expiration could erode market share, especially if biosimilars or generics enter the market.

Investment and R&D Outlook

Additional R&D investments are ongoing for formulation improvements, combination therapies, and new indications. Market growth capitalizes on incremental innovations and expanded indications rather than blockbuster launches.

How Do External Factors Influence MYCELEX-G’s Financial Outlook?

• Healthcare Policies: Reimbursement policies favoring minimally invasive treatments support growth.
• Regulatory Changes: Approval of competitors or new formulations could impact market share.
• Technological Advances: Development of novel delivery systems or combination therapies might shift demand.
• Epidemiological Trends: Rising skin cancer rates globally sustain demand but could also lead to treatment saturation in developed regions.

What Are the Risks to Market and Financial Performance?

• Pricing pressures: Insurers could negotiate discounts or favor generics.
• Delay in approvals: Regulatory hurdles or market restrictions can slow growth.
• Patent challenges: Patent litigation or expiration may enable generic competition.
• Market saturation: Limited patient population in mature markets could restrict growth.

Key Takeaways

• MYCELEX-G operates within a growing dermatology segment driven by increasing skin cancer prevalence.
• Its competitive advantage relies on efficacy, safety, and formulary access, but faces stiff competition.
• Revenue growth is moderate, supported by global expansion and indication broadening.
• Patent protections defend market exclusivity until around 2030; patent expiry risks generic competition.
• External factors, including healthcare policies and technological innovation, significantly influence market trajectory.

Frequently Asked Questions

1. How does MYCELEX-G differ from other topical treatments?
It combines 5-fluorouracil with specific formulation enhancements, allowing targeted and potentially more effective treatment of actinic keratosis with fewer side effects compared to older formulations like Efudex.

2. What are the main barriers to market growth for MYCELEX-G?
Limited awareness among general practitioners, competition from established products, and pricing pressures limit broader adoption.

3. Are there new indications under development for MYCELEX-G?
Research focuses on expanding indications to include other superficial skin cancers and precancerous conditions, which could increase market size.

4. How vulnerable is MYCELEX-G to patent cliffs?
Patent protection lasts until approximately 2030, after which biosimilar or generic competition could significantly reduce revenues unless new formulations or uses are protected.

5. What market regions offer the greatest growth potential for MYCELEX-G?
Emerging markets in Asia and Latin America show rapid dermatological treatment adoption, presenting significant growth opportunities.

---

Sources:
[1] Markets and Markets. Skin Cancer Treatment Market, 2022-2027.
[2] Company financial filings, 2022.